{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:48:35Z","timestamp":1787024915128,"version":"build-2736575974"},"reference-count":92,"publisher":"Informa UK Limited","issue":"5","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.2217\/imt.15.6","type":"journal-article","created":{"date-parts":[[2015,6,12]],"date-time":"2015-06-12T10:59:21Z","timestamp":1434106761000},"page":"545-561","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":31,"title":["CAR Therapy for Hematological Cancers: can Success Seen in the Treatment of B-Cell Acute Lymphoblastic Leukemia be Applied to Other Hematological Malignancies?"],"prefix":"10.1080","volume":"7","author":[{"given":"Hollie J","family":"Pegram","sequence":"first","affiliation":[{"name":"Department of Medicine,Memorial Sloan Kettering Cancer Center,\rNew York,\rNY,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Medicine,Memorial Sloan Kettering Cancer Center,\rNew York,\rNY,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarwish","family":"Rafiq","sequence":"additional","affiliation":[{"name":"Department of Medicine,Memorial Sloan Kettering Cancer Center,\rNew York,\rNY,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renier J","family":"Brentjens","sequence":"additional","affiliation":[{"name":"Department of Medicine,Memorial Sloan Kettering Cancer Center,\rNew York,\rNY,\rUSA"},{"name":"Center for Cell Engineering,Memorial Sloan Kettering Cancer Center,\rNew York,\rNY,\rUSA"},{"name":"Molecular Pharmacology & Chemistry Program,Memorial Sloan Kettering Cancer Center,\rNew York,\rNY,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2015,6,12]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.2604"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181ac6138"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-018192"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-399287"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005930"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"e_1_3_2_9_1","article-title":"CD19-targeted 19-28z CAR modified autologous T cells induce high rates of complete remission and durable responses in adult patients with relapsed, refractory B-cell ALL","author":"Park JH","year":"2014","unstructured":"Park JH , RiviereI, WangXet al. CD19-targeted 19-28z CAR modified autologous T cells induce high rates of complete remission and durable responses in adult patients with relapsed, refractory B-cell ALL. American Society of Hematology Annual Meeting (Abstract 382)(2014).","journal-title":"American Society of Hematology Annual Meeting"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"e_1_3_2_13_1","article-title":"Adoptive therapy using sleeping beauty gene transfer system and artificial antigen presenting cells to manufacture t cells expressing CD19-specific chimeric antigen receptor","author":"Kebriaei P","year":"2014","unstructured":"Kebriaei P , HulsH, SinghHet al. Adoptive therapy using sleeping beauty gene transfer system and artificial antigen presenting cells to manufacture t cells expressing CD19-specific chimeric antigen receptor. American Society of Hematology Annual Meeting (Abstract 311)(2014).","journal-title":"American Society of Hematology Annual Meeting"},{"key":"e_1_3_2_14_1","article-title":"Therapy of B cell malignancies with CD19-specific chimeric antigen receptor-modified t cells of defined subset composition","author":"Turtle CJ","year":"2014","unstructured":"Turtle CJ , SommermeyerD, BergerCet al. Therapy of B cell malignancies with CD19-specific chimeric antigen receptor-modified t cells of defined subset composition. American Society of Hematology Annual Meeting (Abstract 384)(2014).","journal-title":"American Society of Hematology Annual Meeting"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-438002"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002842"},{"issue":"21","key":"e_1_3_2_17_1","first-page":"717","article-title":"Chimeric antigen receptor T cells directed against CD19 induce durable responses and transient cytokine release syndrome in relapsed, refractory CLL and ALL","volume":"120","author":"Porter DL","year":"2012","unstructured":"Porter DL , GruppSA, KalosMet al. Chimeric antigen receptor T cells directed against CD19 induce durable responses and transient cytokine release syndrome in relapsed, refractory CLL and ALL. ASH Annual Meeting Abstracts120(21), 717 (2012).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_2_18_1","article-title":"Chimeric antigen receptor modified T cells directed against CD19 (CTL019 cells) have long-term persistence and induce durable responses in relapsed, refractory CLL","author":"Kalos M","year":"2013","unstructured":"Kalos M , FreyNV, GruppSAet al. Chimeric antigen receptor modified T cells directed against CD19 (CTL019 cells) have long-term persistence and induce durable responses in relapsed, refractory CLL. American Society of Hematology Annual Meeting (Abstract 4162)(2013).","journal-title":"American Society of Hematology Annual Meeting"},{"key":"e_1_3_2_19_1","article-title":"Randomized, Phase II Dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL","author":"Porter DL","year":"2014","unstructured":"Porter DL , FreyNV, MelenhorstJJet al. Randomized, Phase II Dose optimization study of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed, refractory CLL. American Society of Hematology Annual Meeting (Abstract 1982)(2014).","journal-title":"American Society of Hematology Annual Meeting"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348540"},{"issue":"21","key":"e_1_3_2_21_1","first-page":"1797","article-title":"Impact of the conditioning chemotherapy on outcomes in adoptive T cell therapy: results from a Phase I clinical trial of autologous CD19-targeted T cells for patients with relapsed CLL","volume":"120","author":"Park JH","year":"2012","unstructured":"Park JH , RiviereI, WangXet al. Impact of the conditioning chemotherapy on outcomes in adoptive T cell therapy: results from a Phase I clinical trial of autologous CD19-targeted T cells for patients with relapsed CLL. ASH Annual Meeting Abstracts120(21), 1797 (2012).","journal-title":"ASH Annual Meeting Abstracts"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-384388"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.2025"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-519413"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-311845"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI115717"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-283309"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncb1258"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-017061"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-07-299321"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01219.x"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2107.x"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428190109099331"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.176.5.1319"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-09-457531"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.728287"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-05-284984"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04679.x"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041720"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.2781291"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404970"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0909602"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.8.2655"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-546416"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-400044"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI58814"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.58"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-495531"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-0458"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46110"},{"key":"e_1_3_2_51_1","article-title":"Anti-CD19 CAR T cells administered after low-dose chemotherapy can induce remissions of chemotherapy-refractory diffuse large B-cell lymphoma","author":"Kochenderfer JN","year":"2014","unstructured":"Kochenderfer JN , SomervilleR, LuLet al. Anti-CD19 CAR T cells administered after low-dose chemotherapy can induce remissions of chemotherapy-refractory diffuse large B-cell lymphoma. American Society of Hematology Annual Meeting (Abstract 550)(2014).","journal-title":"American Society of Hematology Annual Meeting"},{"key":"e_1_3_2_52_1","article-title":"Phase IIa Trial of ChimericAntigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas","author":"Schuster SJ","year":"2014","unstructured":"Schuster SJ , SvobodaJ, Dwivedy NastaSet al. Phase IIa Trial of ChimericAntigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas. American Society of Hematology Annual Meeting (Abstract 3087)(2014).","journal-title":"American Society of Hematology Annual Meeting"},{"key":"e_1_3_2_53_1","article-title":"Interim safety analysis: a Phase I trial of high dose therapy and autologous stem cell transplantation followed by infusion of chimeric antigen receptor modified T-cells (19-28z CAR-T) directed against CD19+ B-cells for relapsed and refractory aggressive","author":"Sauter CS","year":"2014","unstructured":"Sauter CS , RiviereI, BernalYJet al. Interim safety analysis: a Phase I trial of high dose therapy and autologous stem cell transplantation followed by infusion of chimeric antigen receptor modified T-cells (19-28z CAR-T) directed against CD19+ B-cells for relapsed and refractory aggressive. American Society of Hematology Annual Meeting (Abstract 677)(2014).","journal-title":"American Society of Hematology Annual Meeting"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-10-387969"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-07-235358"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2008.04.007"},{"issue":"6","key":"e_1_3_2_57_1","first-page":"919","article-title":"Lewis blood group-related antigen expression in normal gastric epithelium, intestinal metaplasia, gastric adenoma, and gastric carcinoma","volume":"88","author":"Kobayashi K","year":"1993","unstructured":"Kobayashi K , SakamotoJ, KitoTet al. Lewis blood group-related antigen expression in normal gastric epithelium, intestinal metaplasia, gastric adenoma, and gastric carcinoma. Am. J. Gastroenterol.88(6), 919\u2013924 (1993).","journal-title":"Am. J. Gastroenterol."},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2010.21"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.154"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V85.8.2005.bloodjournal8582005"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.2741\/4181"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21326"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.026310"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.10.2923"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/683065"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401903"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12282"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2014.62"},{"issue":"12","key":"e_1_3_2_69_1","first-page":"1261","article-title":"Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies","volume":"86","author":"Munoz L","year":"2001","unstructured":"Munoz L , NomdedeuJF, LopezOet al. Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies. Haematologica86(12), 1261\u20131269 (2001).","journal-title":"Haematologica"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-09-529537"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1186\/2050-7771-2-4"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-474056"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3023"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1489"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1483"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.9.3401"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-493361"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.7.2198"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004916"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005661"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2013.12.203"},{"key":"e_1_3_2_83_1","first-page":"489","article-title":"Risk stratification in multiple myeloma, part 1: characterization of high-risk disease","volume":"11","author":"Biran N","year":"2014","unstructured":"Biran N , JagannathS, ChariA. Risk stratification in multiple myeloma, part 1: characterization of high-risk disease. Clin. Adv. Hematol. Oncol.11, 489\u2013503 (2014).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-013-1479-5"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2422"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.205"},{"key":"e_1_3_2_87_1","article-title":"CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma","author":"Benjamin R","year":"2012","unstructured":"Benjamin R , CondominesM, GunsetG, SadelainM. CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma. AACR 103rd Annual Meeting (Abstract 3499)(2012).","journal-title":"AACR 103rd Annual Meeting"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-278218"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-493361"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-2510"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.279"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-337360"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4564"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt.15.6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T13:43:17Z","timestamp":1715953397000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt.15.6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":92,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["10.2217\/imt.15.6"],"URL":"https:\/\/doi.org\/10.2217\/imt.15.6","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2015-06-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}